Yervoy & Opdivo is a combination treatment for patients with newly diagnosed advanced renal cell carcinoma (RCC).
Ipilimumab: 1 mg per kg body weight administered as an intravenous infusion over 30 minutes every 3 weeks for a total of 4 infusions
Nivolumab: 3 mg per kg body weight administered as an intravenous infusion over 30 minutes every 3 weeks for a total of 4 infusions
Treatment will continue with Nivolumab 240mg administered as an intravenous infusion over 30 minutes every 2 weeks. It can also be given at a dose of 480mg every 4 weeks. Your doctor will determine which dose and infusion schedule is most appropriate for you.
Route of Administration: Ipilimumab and nivolumab are given as IV infusions by a healthcare provider in a clinic or medical office.
Schedule: Ipilimumab and nivolumab are given every 3 weeks for 4 infusions. Then Nivolumab will be given every two or 4 weeks depending on the dose.
Dietary restrictions: Follow your doctor’s instructions about any restrictions of food, beverages, medications or activities
For females, tell your doctor if you:
Tell your healthcare provider about all the medications you take (including prescription and non-prescription medicine, vitamins, and herbal supplements) before starting treatment, and also before you add any new medication. Your treatment may affect the way other medicines work and other medicines may affect how ipilimumab and nivolumab work.
Know the medicines you take. Keep a list of them to show your doctor and pharmacist and update the list when you add a new medicine.
Common side effects of ipilimumab and nivolumab include:
These are not all of the possible side effects of ipilimumab and nivolumab. Talk to your healthcare team for more information.
Call your provider and healthcare team at once if you experience any new symptoms.
Yervoy & Opdivo may cause serious side effects. A serious side effect is a side effect that can sometimes become life-threatening. They can happen anytime during treatment or even after your treatment has ended.
Serious side effects may include:
Call your healthcare team immediately if you have any new symptoms.
General information about Yervoy & Opdivo: This patient information sheet summarizes the most important information about Yervoy & Opdivo. If you would like more information, talk with your doctor. Your healthcare provider is the best source of information about your health.
Patient Assistance Program: Access Support is a reimbursement program from the company that markets Yervoy & Opdivo, Bristol-Myers Squibb. To enroll, speak to your healthcare provider, or go to www.BMSAccessSupport.com 1-800-861-0048, 8AM to 8PM ET Monday -Friday
Yervoy Patient Call Center 1-800-861-0048 8AM to 8PM ET Monday –Friday.
Opdivo Patient Call Center 1-855-OPDIVO-1 (1-855-673-4861) 8AM to 8PM ET Monday –Friday.
Adapted from the Yervoy (ipilimumab) package insert. Bristol-Myers Squibb, November 2020 and the Opdivo (nivolumab) package insert. Bristol-Myers Squibb, January 2021.
KCA disclaimer statement: you should rely primarily upon your doctor for medical information.